PFE
Pfizer
October 14, 2026 · market open
- Rarity
- 1.46
- Peak move
- +3.82%
- Float cap
- $161.2B
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines and vaccines to healthcare providers, governments, and patients in roughly 200 countries. Its portfolio spans vaccines such as Prevnar and Comirnaty, cardiovascular drugs including Eliquis, and oncology, immunology, rare disease, and internal medicine treatments. It also sells sterile injectables and biosimilars.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
9 events · 0 from SEC or newswire · 0 timed with the move- Key event
clinical_readoutPfizer showcased clinical data across infectious diseases at IDWeek 2026, including a 25-valent pneumococcal vaccine Phase 2 trial in infants, the LB6V Lyme disease vaccine candidate, and bivalent RSVpreF effectiveness data.
- Key event
layoff_restructuringPfizer confirmed cutting about 150 jobs at its Portage, Michigan manufacturing facility, citing lower production volumes from reduced projected demand for some products made there, with media relations director Steven Danehy saying the layoffs are not performance-related.
- Key event
major_contractEnodia Therapeutics and Pfizer signed a research collaboration and license agreement to discover and develop Sec61 translocon inhibitors, with Enodia receiving an upfront payment plus milestones and tiered royalties and total potential value exceeding $500 million, while Pfizer handles clinical, manufacturing, regulatory and commercial work.
analyst_ratingJ.P. Morgan raised its price target on Pfizer to $30 from $28 while maintaining a Neutral rating.
product_launchPfizer announced availability in Mexico of its updated COVID-19 vaccine for the 2026-2027 winter season, targeting the XFG variant of the JN.1 Omicron lineage.
analyst_ratingGuggenheim reiterated its Buy rating and $31.00 price target on Pfizer ahead of Q3 2026 results, forecasting Q3 revenue of $16.16 billion and EPS of $0.77.
analyst_ratingGuggenheim reiterated its Buy rating on Pfizer in an updated outlook on the stock.
analyst_ratingBMO Capital maintained its Buy rating on Pfizer with a $35 price target on October 12, 2026.
regulatory_approvalChina's NMPA approved an additional adult type 2 diabetes indication for Pfizer's GLP-1 injection licensed from Hangzhou Sciwind, adding glycemic control to its existing weight-management use.